Results 21 to 30 of about 8,356,254 (304)

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension [PDF]

open access: yes, 2011
Background: Endothelin-1 signalling plays an important role in pathogenesis of pulmonary hypertension. Although different endothelin-A receptor antagonists are developed, a novel therapeutic option to cure the disease is still needed.
Norbert Weissmann   +41 more
core   +2 more sources

Cardiovascular pathology in patients with newly diagnosed tuberculosis and chronic obstructive pulmonary disease

open access: yesМедицинский совет, 2021
Introduction. Chronic obstructive pulmonary disease and cardiovascular diseases (arterial hypertension, ischemic heart disease, chronic heart failure) are among the comorbid conditions that mutually aggravate each other.
N. V. Bagisheva   +3 more
doaj   +1 more source

Stem cell therapy in pulmonary hypertension: current practice and future opportunities

open access: yesEuropean Respiratory Review, 2023
Pulmonary hypertension (PH) is a progressive disease characterised by elevated pulmonary arterial pressure and right-sided heart failure. While conventional drug therapies, including prostacyclin analogues, endothelin receptor antagonists and ...
Ruixuan Zheng   +5 more
doaj   +1 more source

THE HEART IN PULMONARY TUBERCULOSIS [PDF]

open access: yesSouthern Medical Journal, 1908
n ...
openaire   +1 more source

Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease

open access: yesPulmonary Circulation, 2018
There are few randomised controlled data to guide management of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD).
R. Condliffe   +3 more
doaj   +1 more source

Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood [PDF]

open access: yes, 2005
BACKGROUND: Pulmonary arterial hypertension (PAH) is a potentially fatal vasculopathy that can develop at any age. Adult-onset disease has previously been associated with mutations in BMPR2 and ALK-1.
Haworth, SG   +22 more
core   +1 more source

Beraprost as initial pharmacologic treatment for pulmonary hypertension related to left to right shunt congenital heart disease [PDF]

open access: yes, 2021
Pulmonary arterial hypertension is a common complication of uncorrected left-to-right shunt congenital heart disease. Beraprost have been used widely to treat pulmonary arterial hypertension in adult.
Shirley Ferlina Lasmono, -   +2 more
core   +1 more source

Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]

open access: yes, 2015
Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Declan P. O'Regan   +13 more
core   +1 more source

A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease

open access: yesERJ Open Research, 2018
European Respiratory Society (ERS) guidelines recommend the assessment of patients with interstitial lung disease (ILD) and severe pulmonary hypertension (PH), as defined by a mean pulmonary artery pressure (mPAP) ≥35 mmHg at right heart catheterisation (
Simon Bax   +17 more
doaj   +1 more source

Treatment of pulmonary hypertension with left heart disease: a concise review [PDF]

open access: yes, 2017
Anish Desai, Shilpa A Desouza Division of Pulmonary and Critical Care Medicine, Winthrop-University Hospital, Mineola, NY, USA Abstract: Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥ 25 mmHg, as determined
Anish Desai   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy